RxDoctor Payments Data

Heather Kramm, MD

Rheumatology · Seattle, WANPI 1770548158

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (53.1%), food and beverage and education — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Johnson & Johnson at 59.3% of the total. Reporting peaked in 2019 at $1,870 and has fallen 98.0% since, to $38 in 2024.

$3,297in general payments, 2019–2025

Across 61 payments — averaging $54.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Pfizer$487
  • Amgen$272
  • Novartis$177
  • AstraZeneca$144
  • AbbVie$56
  • plus $208 from 8 others

What the payments were for

  • Consulting fees$1,75053%
  • Travel & lodging$140%
  • Food & beverage$1,51946%
  • Education$150%

General payments by program year

19
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,297 in reported general payments places this provider in the 70th percentile of 157 rheumatology providers in Washington.

See all rheumatology providers in Washington

Medicare billing

Part B allowed, 2024
$137,369
Medicare patients
109
Services billed
6,887

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Teriparatide35$56,537
KineretAnakinra13$52,014
OtezlaApremilast11$51,286
TymlosAbaloparatide12$31,333
Celecoxib64$1,574
Hydroxychloroquine Sulfate35$1,477
Prednisone118$933
Colchicine24$861
MethotrexateMethotrexate Sodium55$729
Leflunomide25$603
Allopurinol31$319
Meloxicam27$244
Diclofenac Sodium12$242
Gabapentin13$203
Methylprednisolone16$102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$272$51,28611 claims
Radius Health, Inc.Tymlos$15$31,33312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 157 rheumatology providers in Washington.

Other rheumatology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →